Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation

Qing-hua WU; Xue QIU; Tie-xin ZENG; Lin-fang HUANG; Wan LIAO; Jin PEI

doi:10.13422/j.cnki.syfjx.20201248

您当前的位置：

首页 >

文章列表页 >

Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation

Topic on Epidemic Resistance | 更新时间：2020-09-16

- Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 19, Pages: 84-91(2020)
- 作者机构：
  
  1.成都中医药大学药学院，中药资源系统研究与开发利用省部共建国家重点实验室培育基地，成都 611137
  2.中国医学科学院药用植物研究所，北京 100094
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201248
  CLC： R282;R931;R254.3;P96
- Received：09 March 2020，
  
  Published Online：10 April 2020，
  
  Published：05 October 2020
- 稿件说明：
移动端阅览
吴清华,邱雪,曾铁鑫等.新型冠状病毒肺炎疫情下中药资源的重点品种分析及合理配置[J].中国实验方剂学杂志,2020,26(19):84-91.

WU Qing-hua,QIU Xue,ZENG Tie-xin,et al.Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(19):84-91.
吴清华,邱雪,曾铁鑫等.新型冠状病毒肺炎疫情下中药资源的重点品种分析及合理配置[J].中国实验方剂学杂志,2020,26(19):84-91. DOI： 10.13422/j.cnki.syfjx.20201248.

WU Qing-hua,QIU Xue,ZENG Tie-xin,et al.Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(19):84-91. DOI： 10.13422/j.cnki.syfjx.20201248.

摘要

在抗击新型冠状病毒肺炎（COVID-19）疫情中，中医药治疗发挥着举足轻重的作用。通过对国家及26个省（自治区、直辖市）发布用于防治COVID-19的中成药和处方中涉及的资源品种进行收集，共整理推荐中成药241种和处方242首。通过分析筛选出常用药材品种53种，其中中成药组方和处方药味组成中共有的重点品种20种，包括甘草、连翘、广藿香等；同时，还有部分冷背药和民族药在此次疫情中也发挥了重要作用。通过对53种常用药材目前的商品药材来源、再生周期、药用部位、产新情况进行分析，以及对目前COVID-19疫情下的中药资源重点品种的供给、再生能力进行评价，提示可以加大甘草、赤芍等药材的人工栽培力度，控制金银花、板蓝根等家种药材的发展。针对市场需求变化，适时调整中药材生产品种结构和种植面积，提升中药材的质量标准和安全性指标，以期为中药资源的合理配置及疫情下的中药材产业发展提供思路。

Abstract

Traditional Chinese medicine (TCM) plays an important role in the fight against coronavirus diseasef-2019 (COVID-19) epidemic. A total of 241 Chinese patent medicines and 242 prescriptions were recommended by the state and 26 provinces (autonomous regions and municipalities directly under the central government) for the prevention and treatment of COVID-19. A total of 53 varieties of commonly used medicinal materials were selected by analysis

of which 20 were common key varieties in medicinal materials of Chinese patent medicines and prescriptions

including Glycyrrhizae Radix et Rhizoma

Forsythiae Fructus

Pogostemonis Herba

etc. At the same time

some cold-quilt medicines and ethnic medicines also played an important role in the epidemic. By evaluating the supply and regeneration ability of the key varieties of TCM resources under the current COVID-19 epidemic situation

means of the source

regeneration cycle

medicinal parts

new production and market information of 53 kinds of TCM at present

it is suggested that the artificial cultivation of Glycyrrhizae Radix et Rhizoma and Paeoniae Radix Rubra can be strengthened

the development of Lonicerae Japonicae Flos

Isatidis Radix and other domestic medicinal materials can be controlled. In response to the change in market demand

the production variety structure and planting area of Chinese medicinal materials were timely adjusted to improve the quality standard and safety index of Chinese medicinal materials

and in order to provide ideas for the rational allocation of TCM resources and the development of Chinese medicinal materials industry under the epidemic situation.

关键词

Keywords

references

国家卫生健康委员会 . 截至4月1日24时新型冠状病毒肺炎疫情最新情况 [EB/OL]. http://www.nhc.gov.cn/xcs/yqtb/202004/be27dc3c4a9544b081e2233537e762c3.shtml http://www.nhc.gov.cn/xcs/yqtb/202004/be27dc3c4a9544b081e2233537e762c3.shtml ， 2020-04-02 / 2020-04-02 .

国家卫生健康委员会，国家中医药管理局 . 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml ， 2020-03-04 / 2020-03-08 .

中华人民共和国中央人民政府 . 国务院新闻办就中医药防治新冠肺炎疫情的重要作用及有效药物举行发布会 [EB/OL]. http://www.gov.cn/xinwen/2020-03/23/content_5494694.htm http://www.gov.cn/xinwen/2020-03/23/content_5494694.htm ， 2020-03-23 / 2020-04-02 .

国家卫生健康委员会，国家中医药管理局 . 新型冠状病毒感染的肺炎治疗方案（试行第三版） [EB/OL]. http://bgs.satcm.gov.cn/gongzuodongtai/2020-01-23/12504.html http://bgs.satcm.gov.cn/gongzuodongtai/2020-01-23/12504.html ， 2020-01-22 / 2020-03-08 .

邓凯文，刘文龙，樊启猛，等 . 基于中医药超分子“气析”理论探讨新型冠状病毒致疫病的中医理论现代化研究策略 [J]. 中国实验方剂学杂志， 2020 ， 26 （ 11 ）： 28 - 34 .

刘洋洋，刘春生，曾斌芳，等 . 甘草种质资源研究进展 [J]. 中草药， 2013 ， 44 （ 24 ）： 3593 - 3598 .

王善法 . 中药一物一名及处方调配 [J]. 时珍国医国药， 2000 ， 11 （ 2 ）： 153 .

刘淑琴 . 黑云香挥发油化学成分GC/MS分析 [J]. 内蒙古民族大学学报：自然科学版， 2011 ， 26 （ 5 ）： 515 - 517 .

罗达尚 . 藏药名著《晶珠本草》简介 [J]. 中草药， 1984 ， 15 （ 4 ）： 33 - 34 .

孙兴姣，李红娇，刘婷，等 . 中药民族药麻黄的本草考证 [J]. 中国药业， 2017 ， 26 （ 21 ）： 1 - 3 .

热比亚·阿布力米提 . 浅谈中医和维吾尔医同用一种药物的异同 [J]. 中国民族医药杂志， 2006 ， 12 （ 2 ）： 27 .

杨纯瑜 . 中国芍药属药用植物资源 [J]. 中药材， 1991 ， 14 （ 12 ）： 42 - 45 .

方前波 . 中国芍药属芍药组的分类、分布与药用 [J]. 现代中药研究与实践， 2004 ， 18 （ 3 ）： 28 - 30 .

孙晓媛，于凡，肖伟，等 . 麦冬现代应用的研究进展 [J]. 中国现代中药， 2018 ， 20 （ 11 ）： 1453 - 1458 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treatment of Myocardial Injury from Coronavirus Disease-2019 by Chinese Medicine

Investigation of Research Strategy of Chinese Medicine Nasal Preparations for Treating Coronavirus Disease-2019 Based on Theory of Lung Opening at Nose ——Taking Qingkailing Preparation as an Example

Exploration of Prevention and Treatment of COVID-19 by Regulating Mucosal Immune System with Traditional Chinese Medicine

Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19

Material Basis of Xuanfei Huazhuo Prescription in Treatment of COVID-19 by Multi-target Molecular Docking

Related Author

Hong-xin CAO

Dan-li TANG

Li SHEN

Yi ZHANG

Nan LI

Xiao HUANG

Zi-xuan LIU

Yu-lu ZHANG

Related Institution

China Association of Chinese Medicine

Experimental Research Center，China Academy of Chinese Medical Science

Institute of Basic Theory for Chinese Medicine，China Academy of Chinese Medical Science

Shenwei Pharmaceutical Group Co. Ltd.

Chengdu University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰